

March 4, 2024

Discontinued Tests

Aspergillus niger IgG		ANIGG
Description of Change	Aspergillus niger IgG (ANIGG), is being discontinued by our reference lab and will not be available to order effective Tuesday, 2/20/24. Please contact Technical Support at 877-402-4221 to discuss testing alternatives.	
Effective Date	Tuesday, February 20, 2024	
Test Name	Aspergillus niger IgG	
Test Code	ANIGG	

Platelet Antibodies, Indirect		BAPLA
Description of Change	Platelet Antibodies, Indirect (BAPLA), is being discontinued by our reference lab and will not be available to order effective Tuesday, 2/20/24. Please contact Technical Support at 877-402-4221 to discuss testing alternatives.	
Effective Date	Tuesday, February 20, 2024	
Test Name	Platelet Antibodies, Indirect	
Test Code	BAPLA	

Procainamide and NAPA		PROC
Description of Change	Procainamide and NAPA (PROC), is being discontinued by our reference lab and will not be available to order effective Tuesday, 2/20/24. Please contact Technical Support at 877-402-4221 to discuss testing alternatives.	
Effective Date	Tuesday, February 20, 2024	
Test Name	Procainamide and NAPA	
Test Code	PROC	

Discontinued Test

Adalimumab Activity and Neutralizing Antibody		ADAL
Description of Change	Adalimumab Activity and Neutralizing Antibody (ADAL) is being discontinued by our reference lab and will not be available to order effective Tuesday, 2/21/23. Refer to the new test below, Adalimumab and Antibodies to Adalimumab Quantitation (ADLMB), as a replacement.	
Effective Date	Tuesday, February 20, 2024	
Test Name	Adalimumab Activity and Neutralizing Antibody	
Test Code	ADAL	
Alternate Test	Adalimumab and Antibodies to Adalimumab Quantitation (ADLMB)	

New – Replacement Test

Adalimumab and Antibodies to Adalimumab Quantitation		ADLMB
Effective Date	Tuesday, February 20, 2024	
Test Name	Adalimumab and Antibodies to Adalimumab Quantitation	
Test Code	ADLMB	
CPT Code	80145, 83520	
Methodology	Quantitative Electrochemiluminescent Immunoassay (ECLIA) with Acid Dissociation	
Report Availability	5-9 days	
Reference Range	Adalimumab Quantitation: 0.4 µl/mL or greater Antibodies to Adalimumab Quantitation: 19 ng/mL or less	
Specimen Requirements		
Container	Gold Top, Serum Separator Tube	
Collection	Separate serum from cells ASAP. Transfer serum to plastic aliquot tube and refrigerate.	
Special Instructions	Collect specimens before next scheduled dose of adalimumab or adalimumab biosimilar (trough specimen). Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.	

Discontinued Test

Infliximab or Biosimilar Activity and Neutralizing Antibody		INFXM
Description of Change	Infliximab or Biosimilar Activity and Neutralizing Antibody (INFXM) is being discontinued by our reference lab and will not be available to order effective Tuesday, 2/21/23. Refer to the new test below, Infliximab and Antibodies to Infliximab Quantitation (IFXMB), as a replacement.	
Effective Date	Tuesday, February 20, 2024	
Test Name	Infliximab or Biosimilar Activity and Neutralizing Antibody	
Test Code	INFXM	
Alternate Test	Infliximab and Antibodies to Infliximab Quantitation (IFXMB)	

New – Replacement Test

Infliximab and Antibodies to Infliximab Quantitation		IFXMB
Effective Date	Tuesday, February 20, 2024	
Test Name	Infliximab and Antibodies to Infliximab Quantitation	
Test Code	IFXMB	
CPT Code	80230, 82397	
Methodology	Quantitative Electrochemiluminescence Immunoassay	
Report Availability	5-9 days	
Reference Range	Infliximab Quantitation: 0.5 µl/mL or greater Antibodies to Infliximab Quantitation: 19 ng/mL or less	
Specimen Requirements		
Container	Gold Top, Serum Separator Tube	
Collection	Separate serum from cells ASAP. Transfer 1 mL serum to plastic aliquot tube and refrigerate.	
Special Instructions	Collect specimen before next scheduled dose of infliximab or infliximab biosimilar (trough specimen). Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.	

If you have additional questions regarding these tests, please contact Technical Support between the hours of 8 a.m. and 4:30 p.m. at 877-402-4221.

02132024_v3